Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 October 2014Website:
http://www.corbuspharma.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:47:58 GMTDividend
Analysts recommendations
Institutional Ownership
CRBP Latest News
Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don't have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow.
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.
Small-cap stocks have historically shown better performance compared to larger stocks. After a period of lagging performance, it seemed like small-cap stocks were poised to make a comeback.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corbus Pharmaceuticals (CRBP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Personalized health screening from a “smart toilet”
NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.
Shares of Corbus Pharmaceuticals NASDAQ: CRBP have already experienced a meteoric rise of over 300% year-to-date. This is thanks to fresh news released two Fridays ago, on January 26.
Corbus Pharmaceuticals has experienced a surge in stock price after positive clinical results for their antibody drug conjugate, CRB-701. CRBP is conducting phase 1 studies for CRB-701 in patients with Nectin-4-positive solid tumors, showing favorable tolerability and promising efficacy. The company's financial situation is concerning, with limited cash on hand and the need for significant financing to continue operations.
The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed up nearly 250% last week. The gains happened after favourable pharmaceutical news that saw the stock climb above $29.
Shares of little-known Corbus Pharmaceuticals (NASDAQ: CRBP ) are absolutely skyrocketing today. At the time of writing, CRBP stock is up more than 300%, as investors price in a key announcement from the company.
What type of business is Corbus Pharmaceuticals Holdings?
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
What sector is Corbus Pharmaceuticals Holdings in?
Corbus Pharmaceuticals Holdings is in the Healthcare sector
What industry is Corbus Pharmaceuticals Holdings in?
Corbus Pharmaceuticals Holdings is in the Biotechnology industry
What country is Corbus Pharmaceuticals Holdings from?
Corbus Pharmaceuticals Holdings is headquartered in United States
When did Corbus Pharmaceuticals Holdings go public?
Corbus Pharmaceuticals Holdings initial public offering (IPO) was on 27 October 2014
What is Corbus Pharmaceuticals Holdings website?
https://www.corbuspharma.com
Is Corbus Pharmaceuticals Holdings in the S&P 500?
No, Corbus Pharmaceuticals Holdings is not included in the S&P 500 index
Is Corbus Pharmaceuticals Holdings in the NASDAQ 100?
No, Corbus Pharmaceuticals Holdings is not included in the NASDAQ 100 index
Is Corbus Pharmaceuticals Holdings in the Dow Jones?
No, Corbus Pharmaceuticals Holdings is not included in the Dow Jones index
When does Corbus Pharmaceuticals Holdings report earnings?
The next expected earnings date for Corbus Pharmaceuticals Holdings is 08 August 2024